This article was originally published in The Gray Sheet
FDA's General and Plastic Surgery Devices Advisory Panel will review the firm's premarket approval application for FocalSeal-L surgical sealant at a May 8 meeting. Under agency expedited review since June 1999, the product is designed to reduce or eliminate air leaks following pulmonary surgery
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.